Dossier
Lot: GY825029
Coverage of Lot: GY825029 in the Nexus archive.
- Recall alert: Cetirizine Hydrochloride recalled over cross-contamination
The FDA has issued a nationwide recall of four lots of Cetirizine Hydrochloride Tablets USP 5 mg produced by Unique Pharmaceuticals due to potential cross-contamination with ranitidine. The affected lots, identified by NDC 16571-401-10 and expiration dates 10/2028, may cause severe allergic reactions in individuals sensitive to ranitidine. No adverse effects have been reported, and consumers are advised to contact Rising Pharma Holdings for further information.